{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T21:48:52Z","timestamp":1771364932711,"version":"3.50.1"},"reference-count":21,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,12,4]],"date-time":"2017-12-04T00:00:00Z","timestamp":1512345600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1016\/j.vaccine.2017.11.081","type":"journal-article","created":{"date-parts":[[2017,12,7]],"date-time":"2017-12-07T17:50:11Z","timestamp":1512669011000},"page":"381-387","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["One or two doses of live varicella virus-containing vaccines: Efficacy, persistence of immune responses, and safety six years after administration in healthy children during their second year of life"],"prefix":"10.1016","volume":"36","author":[{"given":"Ouzama","family":"Henry","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jerzy","family":"Brzostek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanna","family":"Czajka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giedra","family":"Leviniene","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olga","family":"Reshetko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Gasparini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Petr","family":"Pazdiora","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Doina","family":"Plesca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Giuseppina","family":"Desole","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rimantas","family":"Kevalas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Gabutti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Povey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruce","family":"Innis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2017.11.081_b0005","unstructured":"WHO. Varicella and herpes zoster vaccines: WHO position paper. Wkly Epidemiol Rec 2014;89:265\u201388."},{"key":"10.1016\/j.vaccine.2017.11.081_b0010","doi-asserted-by":"crossref","first-page":"e1070","DOI":"10.1542\/peds.2005-2085","article-title":"One dose of varicella vaccine does not prevent school outbreaks: is it time for a second dose?","volume":"117","author":"Lopez","year":"2006","journal-title":"Pediatrics"},{"key":"10.1016\/j.vaccine.2017.11.081_b0015","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1093\/jpids\/piv044","article-title":"Impact of the maturing varicella vaccination program on varicella and related outcomes in the United States: 1994\u20132012","volume":"5","author":"Leung","year":"2016","journal-title":"J Ped Infect Dis Soc"},{"key":"10.1016\/j.vaccine.2017.11.081_b0020","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1542\/peds.2010-0962","article-title":"Varicella-related hospitalizations in the United States, 2000\u20132006: the 1-dose varicella vaccination era","volume":"127","author":"Lopez","year":"2011","journal-title":"Pediatrics"},{"key":"10.1016\/j.vaccine.2017.11.081_b0025","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1177\/2051013613515621","article-title":"Successes and challenges in varicella vaccine","volume":"2","author":"Papaloukas","year":"2014","journal-title":"Ther Adv Vaccines"},{"key":"10.1016\/j.vaccine.2017.11.081_b0030","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1136\/adc.2007.126243","article-title":"Impact of universal varicella vaccination on 1-year-olds in Uruguay: 1997\u20132005","volume":"93","author":"Quian","year":"2008","journal-title":"Arch Dis Child"},{"key":"10.1016\/j.vaccine.2017.11.081_b0035","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/1741-7015-7-26","article-title":"Varicella vaccination in Europe \u2013 taking the practical approach","volume":"7","author":"Bonanni","year":"2009","journal-title":"BMC Med"},{"key":"10.1016\/j.vaccine.2017.11.081_b0040","unstructured":"EMA. Priorix \u2013 summary of product characteristics. Available at <http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Referrals_document\/Priorix_30\/WC500124199.pdf> [accessed Feb 2017]."},{"key":"10.1016\/j.vaccine.2017.11.081_b0045","unstructured":"Varilrix. Product information. Available at <https:\/\/au.gsk.com\/media\/265139\/varilrix_pi_008_approved.pdf> [accessed Feb 2017]."},{"key":"10.1016\/j.vaccine.2017.11.081_b0050","doi-asserted-by":"crossref","first-page":"4278","DOI":"10.1016\/j.vaccine.2016.07.009","article-title":"The immunogenicity and safety of a tetravalent measles-mumps-rubella-varicella vaccine when co-administered with conjugated meningococcal C vaccine to healthy children: a phase IIIb, randomized, multi-center study in Italy","volume":"34","author":"Durando","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.11.081_b0055","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1007\/s15010-007-6337-z","article-title":"Safety and immunogenicity of early vaccination with two doses of tetravalent measles-mumps-rubella-varicella (MMRV) vaccine in healthy children from 9 months of age","volume":"35","author":"Goh","year":"2007","journal-title":"Infection"},{"key":"10.1016\/j.vaccine.2017.11.081_b0060","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1097\/01.inf.0000195626.35239.58","article-title":"Immunogenicity and safety of two doses of tetravalent measles-mumps-rubella-varicella vaccine in healthy children","volume":"25","author":"Knuf","year":"2006","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2017.11.081_b0065","doi-asserted-by":"crossref","first-page":"e007202","DOI":"10.1136\/bmjopen-2014-007202","article-title":"Immunogenicity and safety of early vaccination with two doses of a combined measles-mumps-rubella-varicella vaccine in healthy Indian children from 9 months of age: a phase III, randomised, non-inferiority trial","volume":"5","author":"Lalwani","year":"2015","journal-title":"BMJ Open"},{"key":"10.1016\/j.vaccine.2017.11.081_b0070","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1016\/S0140-6736(12)61461-5","article-title":"Protection against varicella with two doses of combined measles-mumps-rubella-varicella vaccine versus one dose of monovalent varicella vaccine: a multicentre, observer-blind, randomised, controlled trial","volume":"383","author":"Prymula","year":"2014","journal-title":"The Lancet"},{"key":"10.1016\/j.vaccine.2017.11.081_b0075","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"Ethical principles for medical research involving human subjects","volume":"310","author":"World Medical Association Declaration of Helsinki","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2017.11.081_b0080","unstructured":"ICH. Guideline for good clinical practice; 1996. <https:\/\/www.ich.org\/fileadmin\/Public_Web_Site\/ICH_Products\/Guidelines\/Efficacy\/E6\/E6_R1_Guideline.pdf> [accessed Feb 2017]."},{"key":"10.1016\/j.vaccine.2017.11.081_b0085","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1056\/NEJM200103293441302","article-title":"The effectiveness of the varicella vaccine in clinical practice","volume":"344","author":"V\u00e1zquez","year":"2001","journal-title":"New Engl J Med"},{"key":"10.1016\/j.vaccine.2017.11.081_b0090","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1128\/JVI.66.2.1016-1020.1992","article-title":"Restriction fragment length polymorphism of polymerase chain reaction products from vaccine and wild-type varicella-zoster virus isolates","volume":"66","author":"LaRussa","year":"1992","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2017.11.081_b0095","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1093\/biomet\/26.4.404","article-title":"The use of confidence or fiducial limits illustrated in the case of the binomial","volume":"26","author":"Clopper","year":"1934","journal-title":"Biometrika"},{"key":"10.1016\/j.vaccine.2017.11.081_b0100","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","article-title":"Regression models and life-tables","volume":"34","author":"Cox","year":"1972","journal-title":"J Roy Stat Soc B Met"},{"key":"10.1016\/j.vaccine.2017.11.081_b0105","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1586\/14760584.2015.1057572","article-title":"Immunogenicity and reactogenicity of tetravalent vaccine for measles, mumps, rubella and varicella (MMRV) in healthy children: a meta-analysis of randomized controlled trials","volume":"14","author":"Leung","year":"2015","journal-title":"Expert Rev Vaccines"}],"updated-by":[{"DOI":"10.1016\/j.vaccine.2018.09.022","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2018,10,29]],"date-time":"2018-10-29T00:00:00Z","timestamp":1540771200000}}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X17317243?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X17317243?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,29]],"date-time":"2024-06-29T14:37:40Z","timestamp":1719671860000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X17317243"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":21,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["S0264410X17317243"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2017.11.081","relation":{"erratum":[{"id-type":"doi","id":"10.1016\/j.vaccine.2018.09.022","asserted-by":"object"}]},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"One or two doses of live varicella virus-containing vaccines: Efficacy, persistence of immune responses, and safety six years after administration in healthy children during their second year of life","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2017.11.081","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 GlaxoSmithKline SA. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}